Leukemias related to treatment with DNA topoisomerase II inhibitors.
about
Metnase mediates resistance to topoisomerase II inhibitors in breast cancer cellsPanhandle and reverse-panhandle PCR enable cloning of der(11) and der(other) genomic breakpoint junctions of MLL translocations and identify complex translocation of MLL, AF-4, and CDK6.(-)-Epigallocatechin gallate, a major constituent of green tea, poisons human type II topoisomerasesBioflavonoids as poisons of human topoisomerase II alpha and II betaDietary polyphenols as topoisomerase II poisons: B ring and C ring substituents determine the mechanism of enzyme-mediated DNA cleavage enhancementMms22p protects Saccharomyces cerevisiae from DNA damage induced by topoisomerase IILinking Pesticide Exposure with Pediatric Leukemia: Potential Underlying MechanismsThe Structure of DNA-Bound Human Topoisomerase II Alpha: Conformational Mechanisms for Coordinating Inter-Subunit Interactions with DNA CleavageThe benzene metabolite, hydroquinone and etoposide both induce endoreduplication in human lymphoblastoid TK6 cellsRadiation dose-rate effects, endogenous DNA damage, and signaling resonanceMechanisms of chromosomal rearrangement in the human genomeRecurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomideATM modulates the loading of recombination proteins onto a chromosomal translocation breakpoint hotspot.Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastomaNear-precise interchromosomal recombination and functional DNA topoisomerase II cleavage sites at MLL and AF-4 genomic breakpoints in treatment-related acute lymphoblastic leukemia with t(4;11) translocationMutation of cysteine residue 455 to alanine in human topoisomerase IIalpha confers hypersensitivity to quinones: enhancing DNA scission by closing the N-terminal protein gate.Quinone-induced enhancement of DNA cleavage by human topoisomerase IIalpha: adduction of cysteine residues 392 and 405.Early G2/M checkpoint failure as a molecular mechanism underlying etoposide-induced chromosomal aberrations.The MLL recombinome of acute leukemias in 2013.Chemoreduction improves eye retention in patients with retinoblastoma: a report from the German Retinoblastoma Reference Centre.Interactions between the etoposide derivative F14512 and human type II topoisomerases: implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavageAcidic pH induces topoisomerase II-mediated DNA damage.Fe3O4 nanoparticles with daunorubicin induce apoptosis through caspase 8-PARP pathway and inhibit K562 leukemia cell-induced tumor growth in vivo.Yeast recombination pathways triggered by topoisomerase II-mediated DNA breaks.CdTe quantum dots with daunorubicin induce apoptosis of multidrug-resistant human hepatoma HepG2/ADM cells: in vitro and in vivo evaluationRoles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies.Sulfonoquinovosyl diacylglyceride selectively targets acute lymphoblastic leukemia cells and exerts potent anti-leukemic effects in vivo.Treatment-related myelodysplastic syndrome/acute myeloid leukemia in survivors of childhood cancer--an update.Mitoxantrone-associated acute myelogenous leukemia in a patient with high-risk adenocarcinoma of the prostate: a case report and brief review.Second cancers in patients with the Ewing sarcoma family of tumours.DNA topoisomerase II, genotoxicity, and cancerRole of nitric oxide in the chemistry and anticancer activity of etoposide (VP-16,213).Do non-genomically encoded fusion transcripts cause recurrent chromosomal translocations?The efficacy of topoisomerase II-targeted anticancer agents reflects the persistence of drug-induced cleavage complexes in cellsDNA Topology and Topoisomerases: Teaching a "Knotty" Subject.The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothingImpact of the C-terminal domain of topoisomerase IIalpha on the DNA cleavage activity of the human enzyme.Mechanisms of leukemia translocationsUsing 3'-bridging phosphorothiolates to isolate the forward DNA cleavage reaction of human topoisomerase IIalphaAcute leukemia as a secondary malignancy in children and adolescents: current findings and issues.
P2860
Q24319004-608CDC36-604B-4139-A6C3-12EE32D342FAQ24536146-9DABEA68-E4BC-4C6A-9F24-2969CBBB5186Q24627296-6D288527-EB5F-4831-A691-0325C733A0BAQ24627367-D806D156-AEFE-4E75-8184-4B62EACB96C8Q24642324-FA3AC15D-BF89-4D84-8221-8839FB89DDB7Q24791392-59FCA54E-8531-4FF9-BEA8-B28C00BA1C77Q26752627-3FE56D31-547C-46DB-88BC-04012FC83098Q27670934-D6FF5CEF-38A8-4D21-89BC-B7F0309E7A10Q28389453-BB9C00D8-AEBE-4509-8BEB-46B11C66338DQ28392535-86AEBDD6-2B17-4F72-A7DB-08F78C0A73B2Q33531510-4EE9F2A1-E943-48C7-A5B9-CEC50EBB5214Q33566420-AF43919E-79F2-4B43-B24A-2DD6639B791FQ33737465-6B98985B-1B6F-4F8F-8350-BEB79FA5090CQ33836091-F1F6BC9D-E5DB-468F-8EB1-0B7A161DDA82Q33933823-0F8B46B7-2202-4B57-B692-871A3134FDC3Q33944673-B9FB8AD1-33B5-4959-AC14-996660F0E2FAQ33957966-D2806F71-FFAF-4A1A-8DB2-DF5F7B0B8219Q34210998-EF8420F3-DB6D-45CA-8E4E-80F018F15588Q34651113-0B8E347E-1E3A-4848-BCD2-5C83EDD6F881Q34829846-D9B141EB-4B64-40D2-B5BF-C9BCBFCF1033Q34909651-31662A5D-B87A-4EDF-BCCA-4A0E146B509CQ34982407-02D7FFFC-D083-4C1A-850C-F91F6AF1F8A3Q35093591-0281857F-F6DF-42F4-AA35-A23E37C76ACFQ35222177-05FBD827-7035-4AE0-A946-DD3D08453072Q35537180-D3FDD827-F251-4D54-AC1C-9E641F3F6E41Q35865072-EEE6993A-A061-48F0-829C-9175FDAAAAA9Q35865482-83CC4DD6-2351-4C2E-9B9D-B397586B5F5AQ36194631-D23C88AF-E685-43D9-83DB-05D3D7C32794Q36581039-41C223CB-3012-431D-8D20-35014DAAF1AFQ36711750-E5AEFB03-7E58-4B4E-B075-F2C6945A85C4Q36903197-6FFE029A-9CC2-4FFD-87E9-6E19EF3189DAQ36971716-590F9250-7940-414A-B4AE-4D089006D5E0Q37017111-BFBF5BB3-7F12-4103-A812-E52255F98241Q37061217-A316758D-20A1-47A3-9371-EBD6E0F6F653Q37098901-414ED046-F5E2-488B-89B0-B265EAA3A38EQ37108461-19412506-9FD0-4689-AB39-4CDF18E17724Q37184017-C56C7EE2-E8CF-4570-8EBF-7260FFCCEA4FQ37184342-FBD51C2B-439D-4C0C-95CE-CFC52D8D414BQ37323539-64ABB50F-1502-41C1-9FEA-1B30ED3777D9Q37346340-E8D85420-D1C0-44B9-BA0C-D2299D931BE3
P2860
Leukemias related to treatment with DNA topoisomerase II inhibitors.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Leukemias related to treatment with DNA topoisomerase II inhibitors.
@ast
Leukemias related to treatment with DNA topoisomerase II inhibitors.
@en
Leukemias related to treatment with DNA topoisomerase II inhibitors.
@nl
type
label
Leukemias related to treatment with DNA topoisomerase II inhibitors.
@ast
Leukemias related to treatment with DNA topoisomerase II inhibitors.
@en
Leukemias related to treatment with DNA topoisomerase II inhibitors.
@nl
prefLabel
Leukemias related to treatment with DNA topoisomerase II inhibitors.
@ast
Leukemias related to treatment with DNA topoisomerase II inhibitors.
@en
Leukemias related to treatment with DNA topoisomerase II inhibitors.
@nl
P2860
P356
P1476
Leukemias related to treatment with DNA topoisomerase II inhibitors.
@en
P2093
P2860
P304
P356
10.1002/MPO.1125
P577
2001-05-01T00:00:00Z